Drugs / ArabinoFuranosylGuanine [18F]F-AraG
ArabinoFuranosylGuanine [18F]F-AraG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06414902 | Sep 2024 → Oct 2027 expected | esophageal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05663710 Background | Jun 2023 → Oct 2027 | clear cell renal carcinoma | M.D. Anderson Cancer Center | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ArabinoFuranosylGuanine [18F]F-AraG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06414902 ↗ |
| Modality | Diagnostic / imaging agent | “18F-FAraG PET imaging” NCT06414902 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT05663710 ↗ |